Drug Transporter (DT) Information

General Information of DT
DT ID DTD0245
Gene Name SLC28A2
Protein Name Concentrative nucleoside transporter 2
Gene ID
9153
UniProt ID
O43868
TCDB ID
2.A.41.2.4
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 3TIJ_A

Identity: 37.17%

Minimized Score: -1066.343 kcal/mol

Detail: Structure Info

Synonyms CNT 2; CNT2; HsT17153; Na(+)/nucleoside cotransporter 2; SLC28A2; SPNT; SPNT1; Sodium-coupled nucleoside transporter 2; Sodium/nucleoside cotransporter 2; Sodium/purine nucleoside co-transporter; Solute carrier family 28 member 2; hCNT2
DT Family Concentrative Nucleoside Transporter (CNT) Family ;
Tissue Specificity Expressed in heart and skeletal musclefollowed by liver, kidney, intestine, pancreas, placenta andbrain. Weak expression in lung.
Function This sodium-dependent transporter exhibits the transport characteristics of the nucleoside transport system cif or N1 subtype (N1/cif) (selective for purine nucleosides and uridine). Plays a critical role in specific uptake and salvage of purine nucleosides in kidney and other tissues.
Disease(s) Depression [ICD-11: 6A8Z]
Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Endogenous Substrate(s) 2'3'dideoxyinosine cladribrine; Na+; Purines
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Didanosine
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [1]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [2]
Mercaptopurine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [3]
Ribavirin
 Approved Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [4]
Uridine
 Approved Drug Info Depression 6A8Z [5]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Entecavir Approved Drug Info Madin-Darby canine kidney (MDCK) cells-hCNT2 Km = 53.2 microM [2]
References
1 Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals.
2 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
3 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
4 Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
5 Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochem Pharmacol. 2019 May;163:60-70.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.